ライフサイエンスコーパス: binding potential

1 ant (25.8 +/- 7.8%) reduction in [(11)C]DTBZ binding potential.

2 C]P943, for purposes of quantifying regional binding potential.

3 MPBind achieved high prediction accuracy for binding potential.

4 during mitosis by reducing its intrinsic DNA binding potential.

5 reference tissue methods regarding regional binding potential.

6 ametric images of dopamine 2 (D(2)) receptor binding potential.

7 nthesis capacity showed higher D2/3 receptor-binding potential.

8 generate parametric maps of 11C-(R)-PK11195 binding potential.

9 (efflux rate), with no significant impact on binding potential.

10 r molecular docking to assess protein-ligand binding potential.

11 ith changes in regional SERT nondisplaceable binding potential.

12 tatively accurate method for estimating SERT binding potentials.

13 ration was sufficient to quantify VT and the binding potentials.

14 ative to the cerebellar gray matter (R1) and binding potentials.

15 selected as a reference region to calculate binding potentials.

16 Binding potential (a measure of amyloid burden) was calc

17 l connectivity also correlated with baseline binding potential across cortical and extrastriatal subc

18 sporter availability (measured by changes in binding potential) after modafinil when compared with af

19 Ligand binding potentials against individual proteins can be di

20 Calculated binding potentials agreed well between the arterial-inpu

21 ransferase genotype had greater decreases in binding potential (an indirect measure of dopamine relea

22 apillomavirus (HPV) E6 oncoproteins have PDZ binding potential, an activity which is important for th

23 ndent bias in the estimate of tissue-derived binding potential and care must be taken in comparing (1

24 ttern and extrastriatal baseline D2 receptor binding potential and its change after amphetamine admin

25 ns to the linker are designed to improve the binding potential and pharmacokinetics for theranostic a

26 agonist of alpha4beta2-nAChRs, that has high binding potential and rapid brain kinetics in baboons.

27 discovered and shown to possess higher CXCR4 binding potential and specificity than 5.

28 rivation of regional distribution volume and binding potential and to determine the repeatability of

29 L1 proteins also exhibit a unique nucleotide-binding potential and, whereas the larger A and B isofor

30 del in which the effects of the shape of the binding potential are used to quantify the kinetic param

31 Binding potentials around 0.8-1.2 were estimated using d

32 otonin synthesis rate capacity and [11C]DASB binding potential as an index of serotonin transporter a

33 issue and enabled the estimation of regional binding potential as the outcome measure of specific bin

34 n levels of amyloid load and 11C-(R)-PK11195 binding potentials at a voxel level within subregions of

35 Binding potentials averaged 0.6-0.8 in the cortex and 0.

36 BPIT was supported as a method for regional binding potential, B(max), and K(D).

37 -alpha-induced changes in DA2 receptor (D2R) binding potential before and after intravenous amphetami

38 lease was estimated as the percent change in binding potential between conditions (stress and control

39 Understanding the binding potential between MHC and peptides can lead to t

40 omparing the percentage change of raclopride binding potential between the two Parkinson's disease gr

41 inding of [(11)C]raclopride (nondisplaceable binding potential) between baseline values and values fo

42 ), and 3 binding potentials (nondisplaceable binding potential, binding potential relative to total p

43 When using binding potential (BP(F) = B(avail)/K(D) [total availabl

44 f the effects of OPRM1 A118G genotype on MOR binding potential (BP(ND) or receptor availability).

45 SRTM binding potential (BP(ND)) and reference Logan DVR-1 val

46 lated gray matter atrophy on nondisplaceable binding potential (BP(ND)) as determined by a validated

47 The outcome measure was the binding potential (BP(ND)) estimated with the simplified

48 I volume (obtained with RC(zmin) = 50%), the binding potential (BP(ND)) of (11)C-raclopride was found

49 Main Outcome Measure Regional [(11)C]P943 binding potential (BP(ND)) values in an a priori-defined

50 VMAT2 binding potential (BP(ND)) was estimated voxelwise by us

51 [(1)(1)C]DTBZ nondisplaceable binding potential (BP(ND)) was measured by kinetic analy

52 Binding potential (BP(ND)) was quantified before and aft

53 Regional estimates of binding potential (BP(ND)) were obtained by calculating

54 Binding potential (BP(ND)), an index of tracer-specific

55 c modeling was applied to calculate regional binding potential (BP(ND)), and 1- and 2-site binding cu

56 distribution volume (V(T)), nondisplaceable binding potential (BP(ND)), and receptor occupancy.

57 e nondisplaceable striatal D(2)/(3) receptor binding potential (BP(ND)).

58 microdialysis and decrease in [(11)C]FLB 457 binding potential (BP(ND), 0.3 mg kg(-1): -6+/-6%; 0.5 m

59 VAChT binding parameter, the nondisplaceable binding potential (BP(ND-MRTM2)).

60 Parametric images of binding potential (BP) (which is proportional to Bmax/KD

61 crease (P = 0.0012) in mean hypothalamic RAC binding potential (BP) and a significant increase in mea

62 the reproducibility of measurements of SERT binding potential (BP) and relative blood flow (R1) by a

63 DA availability was assessed by measuring D1 binding potential (BP) during rest using PET.

64 ntification methodology capable of producing binding potential (BP) estimates quantitatively comparab

65 applied to each individual's [11C]-WAY100635 binding potential (BP) image to determine the regional r

66 PET, primarily because of their insufficient binding potential (BP) in brain or low penetration throu

67 We examined links between DA D(1) binding potential (BP) in multiple brain regions and IIV

68 io of striatum to brain stem in mice and the binding potential (BP) in the baboon putamen were 3.4 an

69 ized that beer's flavor alone can reduce the binding potential (BP) of [(11)C]raclopride (RAC; a refl

70 lthy controls, had bilaterally decreased RAC binding potential (BP) to striatal dopamine D2/D3 recept

71 Binding potential (BP) was estimated using the ratio met

72 ncorrected P < 0.05) reductions of 18F-FCWAY binding potential (BP) were detected in both mesial and

73 We correlated changes in [(123)I]IBZM binding potential (BP) with plasma levels of homovanilli

74 nstrate that FM patients display reduced MOR binding potential (BP) within several regions known to p

75 utcome measures: distribution volume (V(T)), binding potential (BP), and specific to nonspecific equi

76 anges in the 5HT transporter and 2A receptor binding potential (BP).

77 The binding potential (BP; proportional to receptor concentr

78 tal distribution volumes and nondisplaceable binding potentials (BP(ND)) were used to compare regiona

79 of mu-opioid receptor availability in vivo (binding potential [BP]) were obtained with positron emis

80 SERT and 5-HT(2A) receptor availability (binding potential, BP(ND)) were analyzed with a two-tiss

81 imation in graphical analysis [LEGA]), using binding potential (BPF = Bmax/Kd) (Bmax = maximum number

82 free-fraction measurement to estimate 5-HT1A binding potential (BPF = Bmax/KD, where Bmax = available

83 The binding potential (BPF) of [11C]WAY-100635 (calculated a

84 h methods, all patients had clearly elevated binding potential (BPND (non-displaceable binding potent

85 For binding potential (BPND and BPP), the test-retest variab

86 s not related to a change in nondisplaceable binding potential (BPND) but rather to an increase in th

87 inding potential relative to nondisplaceable binding potential (BPND) by multilinear analysis, simpli

88 D2-type receptor availability, indicated by binding potential (BPND) for [(18)F]fallypride.

89 Parametric nondisplaceable binding potential (BPND) images were compared with stand

90 on, were applied to generate nondisplaceable binding potential (BPND) images.

91 The percentage change in binding potential (BPND) in the DLPFC following amphetam

92 OXT increased [(18)F]MPPF nondisplaceable binding potential (BPND) in the dorsal raphe nucleus (DR

93 10 healthy volunteers), the nondisplaceable binding potential (BPND) obtained from the full kinetic

94 The binding potential (BPND) of (11)C-PBR28 was significantl

95 Regional estimates of the binding potential (BPND) of [(11)C]IMA107 were generated

96 tions and comparing striatal nondisplaceable binding potential (BPND) using a simplified reference ti

97 g allowed calculation of the nondisplaceable binding potential (BPND) values for the binding of (123)

98 Mean striatal nondisplaceable binding potential (BPND) values were 2.0 after injection

99 Binding potential (BPND) values were computed as [(CROI/

100 rves were extracted, and the nondisplaceable binding potential (BPND) was calculated by use of the si

101 njection of the radiotracer, [(11)C]GR103545 binding potential (BPND) was decreased in a dose-depende

102 [(11)C]N-propyl-norapomorphine ([(11)C]NPA) binding potential (BPND) was measured in 14 off-medicati

103 [(11)C]FLB457-binding potential (BPND) was measured pre- and post amph

104 Parametric images of (18)F-FMZ binding potential (BPND) were generated using the simpli

105 Parametric maps of (11)C-(R)PK11195 binding potential (BPND) were generated.

106 tes of regional distribution volume (VT) and binding potential (BPND) with 120 min of scan data.

107 We hypothesized that (11)C-flumazenil binding potential (BPND) would be higher in isoflurane-a

108 or availability (measured as nondisplaceable binding potential (BPND)) in patients with Parkinson's d

109 ne D2-type receptor availability, indexed by binding potential (BPND), and functional magnetic resona

110 methods to estimate the distribution volume, binding potential (BPND), and SUVR.

111 plified models were also tested to calculate binding potential (BPND), including the simplified refer

112 reference tissue models for nondisplaceable binding potential (BPND), supporting noninvasive quantif

113 The outcome measure was the binding potential (BPND), using the cerebellum as the re

114 ) has been used to determine nondisplaceable binding potential (BPND), which is defined as the quotie

115 DA release was measured as change in binding potential (BPND).

116 e of distribution (VND), and nondisplaceable binding potential (BPND); and dosimetry.

117 ormal reductions in striatal nondisplaceable binding potential (BPND)] responses to MP.

118 and, second, to measure the nondisplaceable binding potential (BPND, or the ratio of specific-to-non

119 dings to common coordinates for mouse brain, binding potentials (BPND) and standardized uptake value

120 The binding potentials (BPND) of (11)C-Lu AE92686 in the str

121 PET data were quantified to nondisplaceable binding potentials (BPND) using the Logan graphical anal

122 upply both DAT availability (nondisplaceable binding potential [BPND]) and relative cerebral blood fl

123 g in vivo measures of receptor availability (binding potential, BPND) and DA release (change in BPND

124 atal dopamine D2-type receptor availability (binding potential, BPND) than nonsmokers and exhibit gre

125 Nondisplaceable binding potentials (BPNDs) were calculated using the sim

126 Regional binding potentials (BPNDs) were calculated with the mult

127 Binding potentials (BPnds) were estimated for brain regi

128 Thus, dox and autosomal sites have similar binding potential but are distinguished by linkage to re

129 e was no difference in serotonin transporter binding potential by genotype in healthy volunteers or i

130 The binding potential calculated from simplified tracer kine

131 (11)C-HOMADAM binding potential calculated from the simplified referen

132 de have lower midbrain serotonin transporter binding potential compared with those who do not attempt

133 significantly decreased in both hippocampi (binding potential: controls 1.62 +/- 0.07; ADs 1.18 +/-

134 5-HT(2A) receptor binding potential correlated negatively with age in both

135 measured striatal dopamine D2-like receptor binding potential (D2BP) using positron emission tomogra

136 ion of sweetness intensity, and striatal D2R binding potential (D2R BPND) using positron emission tom

137 after amphetamine (change in nondisplaceable binding potential, DeltaBP(ND)) in subregions of the str

138 Percent change in [(11)C]-(+)-PHNO-binding potential (DeltaBPND) was compared between group

139 etamine-induced displacement of [11C]FLB 457 binding potential (DeltaBPND) was significantly smaller

140 ted with a low bias toward identity with the binding potential derived from a reference region (olfac

141 The volume of distribution and binding potential determined with kinetic modeling were

142 clusters and areas of significantly reduced binding potential (determined using Statistical Parametr

143 Binding potential did not differ between suicide attempt

144 P = .38), and midbrain serotonin transporter binding potential did not predict future attempts (log-r

145 Serotonin transporter binding potential differed significantly by brain region

146 Parametric images of RAC binding potential during performance of each task were g

147 Binding potential estimates from thirty-five 11C-PBR28 P

148 omycin reflect the importance of noncovalent binding potential, even for covalent inhibitors, in ensu

149 The binding potential extrapolated from graphical analysis o

150 Serotonin transporter binding potential (f(1)B(max)/K(d)) was determined by us

151 Serotonin transporter binding potential (f(1)B(max)/K(d)) was determined using

152 duction of ventral striatum (11)C-raclopride binding potential following reward-related cue exposure,

153 Our findings demonstrate that PET-measured binding potentials for CFT and DTBZ for a midbrain volum

154 re used to estimate distribution volumes and binding potentials, for which the cerebellum was used as

155 Voxelwise binding potential ([Formula: see text]) and SUV ratio ([

156 The binding potential images then were spatially normalized,

157 idal intent was not predicted by serotonin1A binding potential in any brain region (F1,10 = 0.83; P =

158 Modafinil also decreased [(11)C]cocaine binding potential in caudate (53.8% [13.8%]; 95% CI, 43.

159 afinil decreased mean (SD) [(11)C]raclopride binding potential in caudate (6.1% [6.5%]; 95% confidenc

160 ging paradigm to assess 1) 5-HT(2A) receptor binding potential in euthymic subjects with a history of

161 Similarly, the (18)F-GE180 binding potential in hippocampus was highest to lowest i

162 lacebo, OT significantly reduced [(11)C]DASB binding potential in right amygdala, insula, and hippoca

163 or nearly significant reductions of regional binding potential in subjects with CD in three regions:

164 Post hoc analysis revealed lower binding potential in subjects with major depressive diso

165 ive episode have lower serotonin transporter binding potential in the amygdala and midbrain, compared

166 rated significantly higher 5-HT(2A) receptor binding potential in the frontal cortex (mean increase:

167 By autoradiography, the TSPO radiotracer binding potential in the injected hemisphere was increas

168 : To determine whether serotonin transporter binding potential in the lower midbrain predicts future

169 No correlation was found between binding potential in the midbrain and severity of depres

170 not attempt suicide, and higher serotonin1A binding potential in the raphe nuclei (RN) is associated

171 controls was reflected by elevated [11C]DASB binding potential in the raphe nuclei region, caudate nu

172 significant reductions in [(11)C]raclopride binding potential in the striatum as a percentage of the

173 [(11)C]DTBZ binding potential in the striatum was derived using the

174 ecrease in ventral caudate/nucleus accumbens binding potential in those who smoked compared with thos

175 n serve as a reference region for estimating binding potentials in brain regions.

176 Binding potentials in the striatum and demographic, clin

177 ed binding potential (BPND (non-displaceable binding potential)) in temporal lobes, lateralising acco

178 insula, and hippocampus, whereas [(18)F]MPPF binding potential increased in right amygdala and insula

179 ux rate constant) and a 2.3-fold increase in binding potential (k3/k4) in the 2-tissue-compartment mo

180 Total distribution volume (V(T)) and binding potentials (k3'/k4) of (S)-(-)- and (R)-(+)-(18)

181 onstant kon, dissociation constant koff, and binding potential (kon/koff) in HEK293-hP2X7R cells were

182 e test-retest variability of nondisplaceable binding potential (<10%) and identified the highest nond

183 enil positron emission tomography generating binding potential maps.

184 Binding potential (maximum number of binding sites x aff

185 y of individuals with elevated mean cortical binding potential (MCBP) for PIB rose in an age-dependen

186 ignificant decreases in SERT nondisplaceable binding potential (neocortex, -56%; pallidostriatum, -19

187 orrelation between amygdala response and DRN binding potential (nondisplaceable) (r = -.87, p < .001)

188 Regional estimates of 5-HT1A receptor binding potential (nondisplaceable) were obtained by cal

189 ume (VT), VT normalized by fP (VT/fP), and 3 binding potentials (nondisplaceable binding potential, b

190 erior to (11)C-(R)-PK11195 due to the higher binding potential observed for this ligand.

191 lest bias when compared with nondisplaceable binding potential obtained from LEGA using the metabolit

192 e was the SBR, and the gold standard was the binding potential obtained with wavelet-aided parametric

193 The binding potential of (123)I-ioflupane in the awake state

194 Striatal binding potential of (18)F- AMC20: varied between 0.49 a

195 The authors measured the binding potential of 5-HTT using [11C]DASB in conjunctio

196 eys suggested that anesthesia influenced the binding potential of [(11)C]1 and [(11)C]4 at the NET.

197 In agreement with its binding affinity the binding potential of [(18)F]7a (BPND = 5.3-8.0) in contr

198 thors found no significant difference in the binding potential of [11C]DASB between the recovered dep

199 ls revealed a 3-15-fold increase in relative binding potential of AAV9 particles upon desialylation.

200 strategies that preserve proper folding and binding potential of antibodies by forcing their oriente

201 s) as high-affinity ligands for TTR, but the binding potential of conjugated PCB metabolites such as

202 of recurrent major depression have elevated binding potential of cortical 5-HT(2A) receptors.

203 part, to the overlapping and promiscuous DNA binding potential of different Hox proteins.

204 Based on the calculated basepair-binding potential of each message with the given sRNA re

205 These findings point out that predicting the binding potential of epitopes cannot assume additive and

206 TNFalpha regulates the expression and/or DNA-binding potential of key positive-acting and negative-ac

207 The [11C]methylreboxetine-binding potential of NET availability in the locus coeru

208 hin nonviral RNA, is capable of altering the binding potential of nonviral RNA to levels seen with wi

209 ied region have the ability to transform the binding potential of nonviral RNA?

210 of isolated dislocations is suppressed by a binding potential of purely geometrical origin.

211 the GTP-binding domain is important for GTP-binding potential of RBEL1A, because deletion of this re

212 and after maturation to demonstrate a higher binding potential of schizonts compared to other asexual

213 is TF agnostic and likely describes general binding potential of TFs.

214 rmined at 2.4 A revealing an extended ligand binding potential of the antigen groove and a substantia

215 t and that each site can regulate the ligand binding potential of the beta3 A-domain.

216 This study examined the binding potential of the brain mu-opioid receptor (mu-OR

217 phonate bone imaging, and measurement of the binding potential of the dopamine transporter radioligan

218 ete scaffold-independent analysis of the RNA-binding potential of the four KH domains of KSRP.

219 ratory analyses suggest that the serotonin1A binding potential of the insula (t = 2.41; P = .04), ant

220 The in-depth analysis of the RNA-binding potential of the KH domains of KSRP provides us

221 rticular ligand and that it is the intrinsic binding potential of the protein surface that determines

222 Computational models trained on the binding potential of transcriptional factor (TF) binding

223 PET imaging showed baseline binding potentials of 0.64 +/- 0.07 in the thalamus, 0.5

224 For (11)C-Cimbi-717, nondisplaceable binding potentials of 6.4 +/- 1.2 (n = 6) were calculate

225 was used to estimate quantitative levels of binding potentials of [(11)C](R)-PK11195 in brain region

226 ion in the brain were prepared, and regional binding potentials of NPY2 receptors toward the radiolig

227 The resulting binding potentials of the radioligand declined by 50-60%

228 the mutants showed minimal effects on their binding potential, one showed enhanced binding, and seve

229 ceptor availability in vivo (nondisplaceable binding potential, or BP(ND)) was measured with positron

230 These antibodies acquire promiscuous antigen binding potential post-translationally, after exposure t

231 usions and Relevance: Greater RN serotonin1A binding potential predicted higher suicidal ideation and

232 Higher RN serotonin1A binding potential predicted more suicidal ideation at 3

233 e attempts and whether higher RN serotonin1A binding potential predicts future suicidal ideation and

234 Binding potentials ranging from 2.6 to 4.9 were measured

235 Using a uniform binding potential rather than the water-mediated potenti

236 Parametric maps of [(11)C](R)PK11195 binding potential, rCMRGlc, and [(11)C]PIB uptake were i

237 ed in the corpus callosum, we calculated the binding potential (receptor availability) of the radioli

238 iatal D1- and D2-type receptor availability [binding potential referred to nondisplaceable uptake (BP

239 relative to total plasma concentration, and binding potential relative to free plasma concentration:

240 Parametric images of (11)C-IMA107 binding potential relative to non-displaceable binding (

241 We measured binding potential relative to non-displaceable compartme

242 We determined (11)C-MeNER binding potential relative to nondisplaceable binding po

243 s) and dopamine D2/D3 receptor availability (binding potential relative to nondisplaceable uptake of

244 SUPERPK methodology was used to measure the binding potential relative to the non-specific volume, B

245 tentials (nondisplaceable binding potential, binding potential relative to total plasma concentration

246 Binding potentials relative to non-displaceable binding

247 -(+)-PHNO volumes of distribution (V(T)) and binding potentials relative to the concentration of trac

248 to calculate volume of distribution (VT) and binding potentials relative to the nondisplaceable trace

249 The estimate of target region binding potential (relative to nondisplaceable radioliga

250 s, based on a threshold of the mean cortical binding potential, representing a conversion rate of 3.1

251 A point-mutated HCR/C that lacked GBP2 binding potential retained the ability to bind and enter

252 based on the distribution of [(18)F]AV-1451 binding potential, separated semantic dementia from cont

253 Clusters with significantly reduced binding potential showed virtually no overlap with funct

254 tlas, and percentage injected dose/cm(3) and binding potential (simplified reference tissue model wit

255 [11C]FLB 457 binding potential, specific compared to nondisplaceable

256 ata indicate that lymphostatin has UDP-sugar binding potential that is critical for activity, and is

257 argeting to microvilli is driven by membrane binding potential that is distributed throughout TH1 rat

258 ls caused increases in CBV and reductions in binding potential that were localized to the dopamine-ri

259 Binding potential, the ratio of specifically bound uptak

260 Binding potential, the steady-state ratio of specific bi

261 to accumulate in the nucleus, suggesting GTP binding potential to be important for RBEL1B nuclear loc

262 of a prototypic human antibody that acquires binding potential to glycoprotein (gp) 120 after exposur

263 linking a human protein insert with antigen-binding potential to the constant antibody regions which

264 cified genome for mRNAs that evince basepair-binding potential to the input sRNA sequence.

265 acid decarboxylase), baseline D2/3 receptor-binding potential using [(11)C]raclopride (a weak compet

266 ilability was quantified as non-displaceable binding potential using a kinetic model for reversible l

267 micol to vesicular acetylcholine transporter binding potential value, proportional to vesicular acety

268 ) and identified the highest nondisplaceable binding potential values (from approximately 0.5 in the

269 Binding potential values based on this VOI were in the s

270 Binding potential values can be assessed using the pons

271 Regional binding potential values derived from the multilinear an

272 unculopontine nucleus (rho=0.81, P<.004) and binding potential values in both the thalamus (rho=-0.88

273 The range of regional binding potential values in the baboon brain was from 3.

274 In addition, binding potential values in the thalamus were positively

275 control participants, patients with PSP had binding potential values that were unchanged in the stri

276 s and non-infarcted penumbra was mapped, and binding potential values then computed both within and o

277 Binding potential values, estimated with the cerebellum

278 omise as a PDE2A PET ligand, albeit with low binding potential values.

279 The lower binding potential was more pronounced in the depressed s

280 cal and pallidostriatal SERT nondisplaceable binding potential was negatively correlated with the num

281 SERT nondisplaceable binding potential was quantified in 12 regions of intere

282 Binding potential was significantly reduced in the whole

283 concentration in plasma, proportional to the binding potential) was analyzed using multivariate analy

284 nergy potential is calculated to distinguish binding potential wells from which reaction to 1S2R and

285 Images of binding potential were created using the two-step versio

286 Receptor density and binding potential were determined by saturation and asso

287 icant reductions in the [(11)C]P943 regional binding potential were either retained (anterior cingula

288 er SE, increases in (11)C-PK11195 uptake and binding potential were evident in epileptogenesis-associ

289 Levels of 11C-(R)-PK11195 binding potential were measured in a selection of cortic

290 The regional estimates of binding potential were obtained using a metabolite-corre

291 Regional estimates of binding potential were obtained using a reversible plasm

292 ake value, total volume of distribution, and binding potential were reduced by 38%, 20%, and 40%, res

293 Cerebellar binding potentials were 3.7 for humans, 2.3 for monkeys,

294 cerebellum as the reference region, regional binding potentials were calculated and ranked as follows

295 PK binding potentials were calculated in and around the sit

296 Regional distribution volumes and binding potentials were calculated with 2- and 4-paramet

297 Measured binding potentials were underestimated by 22%-36% when n

298 led to a highly significant reduction in the binding potential, which could be demonstrated using bot

299 as identified as the ligand with the highest binding potential while still possessing reversible kine

300 e correlation of increased 5-HT(2A) receptor binding potential with increased scores on Dysfunctional